WS Investor
01 Oct 2026, 18:23
Regeneron and Sanofi Expand Immunology Alliance in Deal Worth Up to $8 Billion
Regeneron and Sanofi expanded their long-running immunology collaboration to include four next-generation, long-acting antibody programs targeting key pathways involved in type 2 inflammation.
The expanded alliance includes REGN20423, a long-acting IL-13 monoclonal antibody currently in Phase 1 development for atopic dermatitis, along with a long-acting IL-4xIL-13 bispecific antibody and two additional antibodies targeting IL-4 and IL-4Rα. The latter three programs are expected to enter clinical development in 2027.
Under the agreement, Regeneron will receive $1 billion upfront and could earn up to an additional $7 billion in development, regulatory and commercial milestone payments. The companies will share development and commercialization costs and split future global profits 50:50.
Regeneron will lead research and development, while Sanofi will lead global commercialization. The existing profit-sharing arrangement for Dupixent will remain unchanged.
The companies said the expanded collaboration builds on more than two decades of joint work that helped establish Dupixent as a major treatment across multiple type 2 inflammatory diseases, with more than 1.5 million active patients worldwide.
The deal strengthens both companies’ immunology pipelines and gives them a broader set of long-acting therapies that could potentially extend beyond Dupixent into the next generation of treatments for inflammatory diseases.
Regeneron and Sanofi expanded their long-running immunology collaboration to include four next-generation, long-acting antibody programs targeting key pathways involved in type 2 inflammation.
The expanded alliance includes REGN20423, a long-acting IL-13 monoclonal antibody currently in Phase 1 development for atopic dermatitis, along with a long-acting IL-4xIL-13 bispecific antibody and two additional antibodies targeting IL-4 and IL-4Rα. The latter three programs are expected to enter clinical development in 2027.
Under the agreement, Regeneron will receive $1 billion upfront and could earn up to an additional $7 billion in development, regulatory and commercial milestone payments. The companies will share development and commercialization costs and split future global profits 50:50.
Regeneron will lead research and development, while Sanofi will lead global commercialization. The existing profit-sharing arrangement for Dupixent will remain unchanged.
The companies said the expanded collaboration builds on more than two decades of joint work that helped establish Dupixent as a major treatment across multiple type 2 inflammatory diseases, with more than 1.5 million active patients worldwide.
The deal strengthens both companies’ immunology pipelines and gives them a broader set of long-acting therapies that could potentially extend beyond Dupixent into the next generation of treatments for inflammatory diseases.
